Tag
The Chinese Society of Colorectal Surgery consensus (Gut 2026) standardizes use of immune checkpoint inhibitors (ICIs) in locally advanced rectal cancer—diagnostics, perioperative strategies, organ preservation, safety and follow-up.
A prospective cohort study demonstrates that a specialized multidisciplinary approach combining surgical and gastroenterological treatments significantly improves bowel function and quality of life in patients with low anterior resection sy
A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.
Study finds 62% of rectal cancer patients on Watch and Wait receive optimal surveillance, with younger patients showing better adherence. Critical gaps occur in the first year, particularly in initial endoscopic/imaging exams and colonoscop
A national difference-in-differences study found NAPRC accreditation was associated with modest growth in rectal cancer volume and stage I procedural volume, without evidence of increased care fragmentation.
A groundbreaking North American trial reveals that the taTME ‘bottom-up’ surgical approach for rectal cancer offers a 93.7% three-year survival rate and allows 97% of patients to remain stoma-free, fundamentally changing the lan
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
A validated NCDB-derived risk score using age, sex, race, comorbidity, stage, neoadjuvant therapy, length of stay and conversion identifies patients at markedly different 30-day mortality risk after proctectomy (0.8%–4.5%).
The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation
This international multicenter study evaluates total neoadjuvant therapy (TNT) in routine clinical practice for stage II/III rectal adenocarcinoma, demonstrating varied regimen use and confirming TNT’s efficacy across treatment strategies.
The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete res
Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.
Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.
